宫颈癌中免疫细胞浸润和氧化应激的模式。

IF 5.2 Q2 ONCOLOGY
Oncology Reviews Pub Date : 2025-09-11 eCollection Date: 2025-01-01 DOI:10.3389/or.2025.1570071
Andrea Mlambo, Shuyue Su, Qhaweni Dhlamini, Yuyang Zhang
{"title":"宫颈癌中免疫细胞浸润和氧化应激的模式。","authors":"Andrea Mlambo, Shuyue Su, Qhaweni Dhlamini, Yuyang Zhang","doi":"10.3389/or.2025.1570071","DOIUrl":null,"url":null,"abstract":"<p><p>Cervical cancer (CeCa) remains a significant global health burden, with complex interactions between oxidative stress and immune response playing critical roles in its pathogenesis and progression. This review synthesizes current knowledge on the molecular mechanisms linking oxidative stress pathways and immune evasion, particularly focusing on human papillomavirus oncogenes <i>E6</i> and <i>E7</i>. We highlight the dual roles of immune components such as Type 17 T helper (Th17) cells and the antioxidant enzyme superoxide dismutase 2 (SOD2), which exhibit context-dependent tumor-promoting and suppressive functions. While extensive mechanistic insights have been gained, translation to clinical practice remains limited, partly due to inconsistent biomarkers and incomplete understanding of therapeutic resistance. Recent advances in targeted therapies, including mitochondrial inhibitors, Immune checkpoint inhibitors (ICIs) (e.g., pembrolizumab, nivolumab), and <i>PARP</i> inhibitors, demonstrate promise but face translational hurdles such as assay variability and immune-related adverse events. Future research must address gaps including predictive biomarker development, noninvasive monitoring via liquid biopsy, and rational combination therapies integrating redox modulation and immunotherapy. Enhanced multi-omics integration and refined preclinical models are essential to advance personalized treatment strategies for CeCa.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1570071"},"PeriodicalIF":5.2000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460300/pdf/","citationCount":"0","resultStr":"{\"title\":\"Patterns of immune cell infiltration and oxidative stress in cervical cancer.\",\"authors\":\"Andrea Mlambo, Shuyue Su, Qhaweni Dhlamini, Yuyang Zhang\",\"doi\":\"10.3389/or.2025.1570071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cervical cancer (CeCa) remains a significant global health burden, with complex interactions between oxidative stress and immune response playing critical roles in its pathogenesis and progression. This review synthesizes current knowledge on the molecular mechanisms linking oxidative stress pathways and immune evasion, particularly focusing on human papillomavirus oncogenes <i>E6</i> and <i>E7</i>. We highlight the dual roles of immune components such as Type 17 T helper (Th17) cells and the antioxidant enzyme superoxide dismutase 2 (SOD2), which exhibit context-dependent tumor-promoting and suppressive functions. While extensive mechanistic insights have been gained, translation to clinical practice remains limited, partly due to inconsistent biomarkers and incomplete understanding of therapeutic resistance. Recent advances in targeted therapies, including mitochondrial inhibitors, Immune checkpoint inhibitors (ICIs) (e.g., pembrolizumab, nivolumab), and <i>PARP</i> inhibitors, demonstrate promise but face translational hurdles such as assay variability and immune-related adverse events. Future research must address gaps including predictive biomarker development, noninvasive monitoring via liquid biopsy, and rational combination therapies integrating redox modulation and immunotherapy. Enhanced multi-omics integration and refined preclinical models are essential to advance personalized treatment strategies for CeCa.</p>\",\"PeriodicalId\":19487,\"journal\":{\"name\":\"Oncology Reviews\",\"volume\":\"19 \",\"pages\":\"1570071\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460300/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/or.2025.1570071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/or.2025.1570071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

子宫颈癌(CeCa)仍然是一个重要的全球健康负担,氧化应激和免疫反应之间的复杂相互作用在其发病和进展中起着关键作用。本文综述了氧化应激途径和免疫逃避的分子机制,重点介绍了人乳头瘤病毒致癌基因E6和E7。我们强调了免疫成分的双重作用,如17型T辅助细胞(Th17)和抗氧化酶超氧化物歧化酶2 (SOD2),它们表现出依赖于环境的肿瘤促进和抑制功能。虽然已经获得了广泛的机制见解,但将其转化为临床实践仍然有限,部分原因是生物标志物不一致以及对治疗耐药性的理解不完整。靶向治疗的最新进展,包括线粒体抑制剂、免疫检查点抑制剂(ICIs)(如派姆单抗、纳武单抗)和PARP抑制剂,显示出了希望,但面临着转化障碍,如检测变异性和免疫相关不良事件。未来的研究必须解决空白,包括预测性生物标志物开发,通过液体活检进行无创监测,以及结合氧化还原调节和免疫治疗的合理联合治疗。加强多组学整合和完善临床前模型对于推进CeCa的个性化治疗策略至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Patterns of immune cell infiltration and oxidative stress in cervical cancer.

Cervical cancer (CeCa) remains a significant global health burden, with complex interactions between oxidative stress and immune response playing critical roles in its pathogenesis and progression. This review synthesizes current knowledge on the molecular mechanisms linking oxidative stress pathways and immune evasion, particularly focusing on human papillomavirus oncogenes E6 and E7. We highlight the dual roles of immune components such as Type 17 T helper (Th17) cells and the antioxidant enzyme superoxide dismutase 2 (SOD2), which exhibit context-dependent tumor-promoting and suppressive functions. While extensive mechanistic insights have been gained, translation to clinical practice remains limited, partly due to inconsistent biomarkers and incomplete understanding of therapeutic resistance. Recent advances in targeted therapies, including mitochondrial inhibitors, Immune checkpoint inhibitors (ICIs) (e.g., pembrolizumab, nivolumab), and PARP inhibitors, demonstrate promise but face translational hurdles such as assay variability and immune-related adverse events. Future research must address gaps including predictive biomarker development, noninvasive monitoring via liquid biopsy, and rational combination therapies integrating redox modulation and immunotherapy. Enhanced multi-omics integration and refined preclinical models are essential to advance personalized treatment strategies for CeCa.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncology Reviews
Oncology Reviews ONCOLOGY-
CiteScore
6.30
自引率
0.00%
发文量
9
审稿时长
9 weeks
期刊介绍: Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信